Cancer Cell Patents (Class 424/174.1)
  • Patent number: 11174320
    Abstract: Isolated or recombinant anti-HER3 monoclonal antibodies are provided. In some cases, antibodies of the embodiments can be used for the detection, diagnosis and/or therapeutic treatment of human diseases, such as cancer.
    Type: Grant
    Filed: June 14, 2019
    Date of Patent: November 16, 2021
    Assignee: THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM
    Inventors: Ningyan Zhang, Zhiqiang An
  • Patent number: 11167008
    Abstract: Disclosed herein are compositions comprising immunomodulatory and oncolytic eubacterial minicells, and the use of the composition in immunomodulatory therapies for cancer. In some embodiments, the minicells are used in combination of immune checkpoint inhibitors in treating cancer.
    Type: Grant
    Filed: November 21, 2017
    Date of Patent: November 9, 2021
    Assignee: VAXIION THERAPEUTICS, LLC
    Inventor: Matthew J. Giacalone
  • Patent number: 11124498
    Abstract: Disclosed herein, inter alia, are compositions for modulating protease activity and treating cancer.
    Type: Grant
    Filed: November 15, 2017
    Date of Patent: September 21, 2021
    Assignees: THE REGENTS OF THE UNIVERSITY OF CALIFORNIA, MASSACHUSETTS INSTITUTE OF TECHNOLOGY, PRESIDENT AND FELLOWS OF HARVARD COLLEGE
    Inventors: Michael A. Fischbach, Chun-Jun Guo, Christopher A. Voigt, Fang-Yuan Chang, Jon Clardy, Thomas Wyche
  • Patent number: 11117977
    Abstract: Embodiments described herein provide anti-fibulin-3 antibodies, recombinant proteins that bind specifically to fibulin-3, compositions and the treatment methods comprising these antibodies and recombinant proteins.
    Type: Grant
    Filed: January 30, 2019
    Date of Patent: September 14, 2021
    Assignee: THE BRIGHAM AND WOMEN'S HOSPITAL, INC.
    Inventors: Mariano S. Viapiano, Nandhu Mohan Sobhana, Ennio Antonio Chiocca
  • Patent number: 11104732
    Abstract: The present disclosure relates to a modified cell comprising a polynucleotide encoding a secretable scFv binding SIGLEC-15 and/or encoding a dominant negative form of CD44. In embodiments, the modified cell further comprises an antigen-binding molecule, which for example, is a CAR comprising an antigen-binding domain, a transmembrane domain, and an intracellular signaling domain.
    Type: Grant
    Filed: April 23, 2020
    Date of Patent: August 31, 2021
    Inventors: Zhiyuan Cao, Chengfei Pu, Lei Xiao
  • Patent number: 11072662
    Abstract: Provided herein are humanized antibodies specific for CLL-1.
    Type: Grant
    Filed: November 22, 2016
    Date of Patent: July 27, 2021
    Assignee: Cellerant Therapeutics, Inc.
    Inventors: Ying-Ping Jiang, Jagath R. Junutula, Leonard G. Presta, Naoya Tsurushita
  • Patent number: 11027023
    Abstract: The present invention provides a natural type miRNA, which is a single-stranded nucleic acid containing X region and Y region, wherein the 3?-terminus of said X region and the 5?-terminus of said Y region are linked via a linker region of a non-nucleotide structure, the X region contains (a) a guide strand sequence or (b) a passenger strand sequence of a mature miRNA, when the X region contains (a), the Y region contains a passenger strand sequence of the mature miRNA, when the X region contains (b), the Y region contains a guide strand sequence of the mature miRNA, and the guide strand sequence and the passenger strand sequence form a double-stranded structure.
    Type: Grant
    Filed: December 25, 2015
    Date of Patent: June 8, 2021
    Assignee: BONAC CORPORATION
    Inventors: Eriko Aoki, Yasuhiko Yoshida, Shiori Kato, Tadaaki Ohgi
  • Patent number: 10881719
    Abstract: It is disclosed herein methods of treating prostate cancer comprising administering to the subject the combination of androgen deprivation therapy (ADT) and a vaccine directed against the androgen receptor or a fragment of the androgen receptor. Also disclosed are methods of increasing the efficacy of androgen deprivation therapy in a subject with prostate cancer comprising administering to the subject an effective amount of a vaccine against the androgen receptor or fragments thereof wherein the method inhibits, delays or reduces the growth of the prostate cancer and/or the development of castration-resistant prostate cancer.
    Type: Grant
    Filed: June 9, 2017
    Date of Patent: January 5, 2021
    Assignee: WISCONSIN ALUMNI RESEARCH FOUNDATION
    Inventors: Douglas McNeel, Brian Olson
  • Patent number: 10881654
    Abstract: Methods and pharmaceutical compositions for inhibiting 6-phosphofructo-2-kinase/fructose-2,6-biphosphatase 4 (PFKFB4) and the treatment of cancer are described.
    Type: Grant
    Filed: April 22, 2016
    Date of Patent: January 5, 2021
    Assignee: UNIVERSITY OF LOUISVILLE RESEARCH FOUNDATION, INC.
    Inventors: Sucheta Telang, Jason Chesney, John O. Trent
  • Patent number: 10869906
    Abstract: The present invention relates, in general, to a method of treating patients undergoing enzyme replacement therapy (ERT) or other therapy involving the administration of a proteinaceous therapeutic agent as well gene replacement therapy with non-viral or viral vectors, or other therapeutic modality or modalities, used alone or in combination, which involve the administration of exogenous substances for potential therapeutic benefit, including, but not limited to DNA vaccines, siRNA, splice-site switching oligomers (SSOs) as well as RNA-based nanoparticles (RNPs) and nanovaccines. The invention further relates to compounds and compositions suitable for use in such methods.
    Type: Grant
    Filed: October 27, 2017
    Date of Patent: December 22, 2020
    Assignee: DUKE UNIVERSITY
    Inventors: Priya S. Kishnani, Suhrad G. Banugaria, Dwight D. Koeberl, Sean N. Prater
  • Patent number: 10829560
    Abstract: The disclosure relates to agents binding specifically to human cadherin 17 (CDH17), and/or to human cadherin 5 (CDH5), and/or to human cadherin 6 (CDH6), and/or to human cadherin 20 (CDH20). The disclosure also relates to the use of these agents in therapy, methods for diagnosis and/or prognosis and/or stratification of a cancer in a subject, and pharmaceutical compositions comprising said agents. The disclosure also relates to cancer markers and markers of metastasis.
    Type: Grant
    Filed: April 20, 2015
    Date of Patent: November 10, 2020
    Assignee: CONSEJO SUPERIOR DE INVESTIGACIONES CIENTIFICAS
    Inventors: José Ignacio Casal Álvarez, Rubén Álvaro Bartolome Conde
  • Patent number: 10828281
    Abstract: The present invention is directed to compounds, tautomers, stereoisomers, and chemically modified compounds thereof, and their use in preventing and/or treating tumors of metastasis and/or cartilage defect, and to a pharmaceutical composition comprising such compound.
    Type: Grant
    Filed: May 24, 2016
    Date of Patent: November 10, 2020
    Assignee: Friedrich-Alexander-Universität Erlangen-Nürnberg
    Inventors: Anja-Katrin Bosserhoff, Alexander Riechers, Burkhard König, Manuel Bause, Fabian Rauscher
  • Patent number: 10800852
    Abstract: There is disclosed compositions and methods relating to or derived from anti-CD38 antibodies. More specifically, there is disclosed fully human antibodies that bind CD38, CD38-antibody binding fragments and derivatives of such antibodies, and CD38-binding polypeptides comprising such fragments. Further still, there is disclosed nucleic acids encoding such antibodies, antibody fragments and derivatives and polypeptides, cells comprising such polynucleotides, methods of making such antibodies, antibody fragments and derivatives and polypeptides, and methods of using such antibodies, antibody fragments and derivatives and polypeptides, including methods of treating a disease.
    Type: Grant
    Filed: August 4, 2018
    Date of Patent: October 13, 2020
    Assignee: Sorrento Therapeutics, Inc.
    Inventors: Heyue Zhou, John Dixon Gray
  • Patent number: 10801025
    Abstract: Methods for inhibiting pancreatic cancer cell migration and invasion are disclosed herein. Further, methods for inhibiting autophagy are disclosed. More particularly, as discussed herein, increasing miR-29 expression in the tumor microenvironment inhibits migration, invasion and autophagy in cancer patients.
    Type: Grant
    Filed: July 26, 2017
    Date of Patent: October 13, 2020
    Assignee: Indiana University Research and Technology Corporation
    Inventor: Janaiah Kota
  • Patent number: 10780117
    Abstract: Therapeutic and diagnostic methods are provided, which methods relate to the induction of expression of calreticulin on phagocytic cells. Specifically, the methods relate to macrophage-mediated programmed cell removal (PrCR), the methods comprising increasing PrCR by contacting a phagocytic cell with a toll-like receptor (TLR) agonist; or down-regulating PrCR by contacting a phagocytic cell with an inhibitor of Bruton's tyrosine kinase (BTK). In some embodiments, an activator of TLR signaling or a BTK agonist is provided in combination with CD47 blockade.
    Type: Grant
    Filed: January 21, 2016
    Date of Patent: September 22, 2020
    Assignee: The Board of Trustees of the Leland Stanford Junior University
    Inventors: Irving L. Weissman, Mingye Feng, Jens-Peter Volkmer
  • Patent number: 10752686
    Abstract: Described is a bispecific antibody, and a method for producing the bispecific antibody. The bispecific antibody can be used in the preparation of a drug for treating a tumor with high cell expression of CD26. The antibody specifically hinds to human CD26 and human CD3 at the same time.
    Type: Grant
    Filed: October 30, 2015
    Date of Patent: August 25, 2020
    Assignees: ZONHON BIOPHARMA INSTITUTE INC., GENSUN INSTITUTE OF BIOMEDICINE CO., LTD.
    Inventors: Yong Ma, Peipei Cao, Anliang Wang
  • Patent number: 10736950
    Abstract: The invention relates to prophylaxis and therapy of cancer. In particular there is provided a protein Tryptophan2,3-di-oxygenase (TDO) or peptide fragments here of that are capable of eliciting anti-cancer immune responses. Specifically, the invention relates to the use of TDO or peptides derived thereof or TDO specific T-cells for treatment of cancer. The invention thus relates to an anti-cancer vaccine which optionally may be used in combination with other immunotherapies and to TDO specific T-cells adoptively transferred or induced in vivo by vaccination as a treatment of cancer. It is an aspect of the invention that the medicaments herein provided may be used in combination with cancer chemotherapy treatment. A further aspect relates to the prophylaxis and therapy of infections by the same means as described above.
    Type: Grant
    Filed: September 15, 2015
    Date of Patent: August 11, 2020
    Assignee: Herlev Hospital
    Inventor: Mads Hald Andersen
  • Patent number: 10662242
    Abstract: Markers of acute myeloid leukemia stem cells (AMLSC) are identified. The markers are differentially expressed in comparison with normal counterpart cells, and are useful as diagnostic and therapeutic targets.
    Type: Grant
    Filed: September 14, 2017
    Date of Patent: May 26, 2020
    Assignee: The Board of Trustees of the Leland Stanford Junior University
    Inventors: Ravindra Majeti, Irving L. Weissman
  • Patent number: 10654903
    Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.
    Type: Grant
    Filed: July 5, 2019
    Date of Patent: May 19, 2020
    Assignee: IMMATICS BIOTECHNOLOGIES GMBH
    Inventors: Andrea Mahr, Toni Weinschenk, Valentina Goldfinger, Oliver Schoor, Jens Fritsche, Harpreet Singh
  • Patent number: 10648983
    Abstract: A method of identifying a subject having cancer who is likely to be responsive to a treatment compound, comprising administering the treatment compound to the subject having the cancer; obtaining a sample from the subject; determining the level of a biomarker in the sample from the subject; and diagnosing the subject as being likely to be responsive to the treatment compound if the level of the biomarker in the sample of the subject changes as compared to a reference level of the biomarker; wherein the treatment compound is a compound of Formula I:
    Type: Grant
    Filed: January 6, 2017
    Date of Patent: May 12, 2020
    Assignee: Celgene Corporation
    Inventors: Ellen Filvaroff, Antonia Lopez-Girona, Gang Lu
  • Patent number: 10639378
    Abstract: The invention relates generally to a silvestrol molecule activated with a leaving group. The invention further relates generally to an antibody-drug conjugate comprising an antibody conjugated by a linker to one or more silvestrol drug moieties and methods of treatment.
    Type: Grant
    Filed: June 5, 2017
    Date of Patent: May 5, 2020
    Assignee: Genentech, Inc.
    Inventors: Thomas Pillow, Andrew G. Polson, Bing Zheng
  • Patent number: 10611848
    Abstract: Antibody which binds to the O-acetylated-GD2 ganglioside, includes: a) a light chain including three light chain complementary regions (CDRs) having the following amino acid sequences: CDR1: QSLLKNNGNTFL (SEQ id no 1), CDR2: KVS, CDR3: SQSTHIPYT (SEQ id no 2); and a light chain framework sequence from an immunoglobulin light chain, including the human kappa (?)CL domain; and b) a heavy chain including three heavy chain complementary regions (CDRs) having the following amino acid sequences: CDR1: EFTFTDYY (SEQ id no 3), CDR2: IRNRANGYTT (SEQ id no 4), CDR3: ARVSNWAFDY (SEQ id no 5), and a heavy chain framework sequence from an immunoglobulin heavy chain, including CH2 and CH3 domains from a human IgG1, and a CH1 domain from a human IgG1, which is mutated to restore pairing between CH1 and light chain that is typical of other human IgG subclasses or substituted by a CH1 domain from such non-IgG1 subclasses as human IgG2, IgG3 or IgG4.
    Type: Grant
    Filed: November 11, 2014
    Date of Patent: April 7, 2020
    Assignees: OGD2 PHARMA, UNIVERSITE DE NANTES
    Inventors: Jean-Marc Le Doussal, Mickael Terme, Mylene Dorvillius
  • Patent number: 10598653
    Abstract: Disclosed herein are antibodies against GPR49 and uses of such antibodies. The antibodies can be monoclonal, humanized, or fully human antibodies against GPR49, hybridomas or other cell lines expressing such antibodies, nucleic acids and vectors comprising nucleic acids encoding for such antibodies, and methods of blocking cancer stem cell growth with such antibodies.
    Type: Grant
    Filed: October 31, 2012
    Date of Patent: March 24, 2020
    Assignee: BIONOMICS INC.
    Inventors: Christopher L. Reyes, Peter Chu, Xiangyang Tan, Weixing Yang, Christilyn Graff
  • Patent number: 10597456
    Abstract: Antigen binding molecules, chimeric receptors, and engineered immune cells are disclosed in accordance with the invention. The invention further relates to vectors, compositions, and methods of treatment and/or detection using the antigen binding molecules and engineered immune cells.
    Type: Grant
    Filed: March 31, 2017
    Date of Patent: March 24, 2020
    Assignees: AMGEN INC., KITE PHARMA, INC.
    Inventors: Jed Wiltzius, Ruben Alvarez Rodriguez, Alice Bakker, Lawren Wu, Tara Arvedson
  • Patent number: 10550188
    Abstract: Disclosed herein are compositions and pharmaceutical formulations that comprise a binding moiety conjugated to a polynucleic acid molecule and a polymer. Also described herein include methods for treating a cancer which utilize a composition or a pharmaceutical formulation comprising a binding moiety conjugated to a polynucleic acid molecule and a polymer.
    Type: Grant
    Filed: September 11, 2018
    Date of Patent: February 4, 2020
    Assignee: AVIDITY BIOSCIENCES, INC.
    Inventors: Andrew John Geall, Venkata Ramana Doppalapudi, David Sai-Ho Chu, Michael Caramian Cochran, Rachel Elizabeth Johns, Palani Balu, Rob Burke, Beatrice Diana Darimont
  • Patent number: 10487149
    Abstract: Disclosed herein are compositions and pharmaceutical formulations that comprise a binding moiety conjugated to a polynucleic acid molecule and a polymer. Also described herein include methods for treating a cancer which utilize a composition or a pharmaceutical formulation comprising a binding moiety conjugated to a polynucleic acid molecule and a polymer.
    Type: Grant
    Filed: September 12, 2018
    Date of Patent: November 26, 2019
    Assignee: AVIDITY BIOSCIENCES, INC.
    Inventors: Andrew John Geall, Venkata Ramana Doppalapudi, David Sai-Ho Chu, Michael Caramian Cochran, Rachel Elizabeth Johns, Palani Balu, Rob Burke, Beatrice Diana Darimont
  • Patent number: 10421776
    Abstract: The present invention relates to a method for preventing the unfolding of a (poly)peptide during drying and/or inducing the (re-)folding of a (poly)peptide after drying, comprising the step of embedding the (poly)peptide in an aqueous solution, wherein the solution comprises (i) at least three different amino acids; or (ii) at least one dipeptide or tripeptide; and wherein the solution is free or substantially free of (a) sugar; and (b-i) protein; and/or (b-ii) denaturing compounds; and (c) silanes.
    Type: Grant
    Filed: January 13, 2016
    Date of Patent: September 24, 2019
    Assignee: Leukocare AG
    Inventors: Martin Scholz, Jens Altrichter, Kristina Kemter
  • Patent number: 10336823
    Abstract: Provided herein are methods of treating B7-H1-expressing tumors comprising administering an effective amount of MEDI4736 or an antigen-binding fragment thereof.
    Type: Grant
    Filed: September 11, 2014
    Date of Patent: July 2, 2019
    Assignee: MedImmune Limited
    Inventors: Rajesh Narwal, David Fairman, Paul Robbins, Meina Liang, Amy Schneider, Carlos Chavez, Carina Herl, Min Pak, Hong Lu, Marlon Rebelatto, Keith Steele, Anmarie Boutrin, Li Shi, Shengyan Hong, Brandon Higgs, Lorin Roskos
  • Patent number: 10300140
    Abstract: Embodiments concern constructs comprising surrogate light chain sequences. In particular, embodiments concern constructs that can bind to ErbB3 and aspects relating to such constructs.
    Type: Grant
    Filed: July 27, 2012
    Date of Patent: May 28, 2019
    Assignee: I2 PHARMACEUTICALS, INC.
    Inventors: Ramesh R. Bhatt, Pamela K. Foreman, Lawrence C. Horowitz, Michael Horowitz, Medini Gore, Phil Kobel
  • Patent number: 10280221
    Abstract: Antigen binding proteins that bind Lymphocyte Activation Gene 3 (LAG-3), and more particularly to antigen binding proteins that cause depletion of LAG-3+ activated T cells.
    Type: Grant
    Filed: March 13, 2014
    Date of Patent: May 7, 2019
    Assignee: GlaxoSmithKline Intellectual Property Development Limited
    Inventors: Paul Andrew Hamblin, Alan Peter Lewis, Thomas Matthew Webb
  • Patent number: 10266603
    Abstract: The invention includes method, pharmaceutical compositions and uses thereof for treating patients with Papillary Thyroid Carcinoma (PTC) using a Platelet Derived Growth Factor Receptor Alpha (PDGFRA) inhibitor. The PDGFRA inhibitor is preferably an antibody specific to PDGFRA and causes an increase in the sensitivity level of PTC cells to radioiodine treatment. Moreover, the antibody can be used in combination with other PDGFRA inhibitors such as tyrosine kinase inhibitors and RNA interference molecules.
    Type: Grant
    Filed: April 17, 2015
    Date of Patent: April 23, 2019
    Assignee: The Governors of the University of Alberta
    Inventors: Todd McMullen, Ana Lopez-Campistrous, David Williams
  • Patent number: 10174385
    Abstract: The technology described herein relates to assays and methods for the diagnosis, prognosis, and/or treatment of melanoma, e.g. relating to measuring the level of neurophilin-2 (NRP-2) mRNA expressed in melanoma cells. In some embodiments, the level of NRP-2 can be normalized to the level of Melan-A (MART) mRNA.
    Type: Grant
    Filed: December 19, 2014
    Date of Patent: January 8, 2019
    Assignee: TRUSTEES OF BOSTON UNIVERSITY
    Inventors: Rhoda M. Alani, Byungwoo Ryu
  • Patent number: 10174360
    Abstract: The present disclosure provides a method for analyzing glyeart-derived monosaccharides in a sample. The present disclosure also provides a method for detecting or monitoring a disease or disorder in a patient. In addition, the present disclosure provides a method of determining aberrant glycotransferase activity. The present disclosure further provides a system for analyzing or comparing glycates in a sample.
    Type: Grant
    Filed: March 14, 2013
    Date of Patent: January 8, 2019
    Assignee: ARIZONA BOARD OF REGENTS, FOR AND ON BEHALF OF, ARIZONA STATE UNIVERSITY
    Inventors: Chad Borges, Douglas Rehder
  • Patent number: 10000756
    Abstract: The invention provides compositions and methods for regulating microRNA (miRNA) biogenesis. The invention also relates to compositions and methods for treating or preventing cancer in a subject in need thereof.
    Type: Grant
    Filed: January 31, 2017
    Date of Patent: June 19, 2018
    Assignee: PRESIDENT AND FELLOWS OF HARVARD COLLEGE
    Inventors: Piotr Sliz, Yunsun Nam
  • Patent number: 9932400
    Abstract: The present invention is directed to bi-specific monovalent diabodies that comprise two polypeptide chains and which possess at least one binding site specific for an epitope of CD3 and one binding site specific for an epitope of gpA33 (i.e., a “gpA33×CD3 bi-specific monovalent diabody”). The present invention also is directed to bi-specific monovalent diabodies that comprise an immunoglobulin Fc Domain (“bi-specific monovalent Fc diabodies”) and are composed of three polypeptide chains and which possess at least one binding site specific for an epitope of gpA33 and one binding site specific for an epitope of CD3 (i.e., a “gpA33×CD3 bi-specific monovalent Fc diabody”). The bi-specific monovalent diabodies and bi-specific monovalent Fc diabodies of the present invention are capable of simultaneous binding to gpA33 and CD3. The invention is directed to pharmaceutical compositions that contain such bi-specific monovalent diabodies or such bi-specific monovalent Fc diabodies.
    Type: Grant
    Filed: August 20, 2014
    Date of Patent: April 3, 2018
    Assignee: MacroGenics, Inc.
    Inventors: Paul A. Moore, Jonathan Li, Francine Zhifen Chen, Leslie S. Johnson, Kalpana Shah, Ezio Bonvini
  • Patent number: 9863948
    Abstract: The present invention relates to a method for the in vitro prediction of the probability of a patient developing severe dengue, based on a blood sample, which involves: a) determining the quantity of at least one marker, and b) comparing the quantity with a reference quantity obtained from a group of individuals who have been diagnosed with non-severe dengue, and if the quantity determined in step a) is greater than the reference quantity established in step b), predicting that the patient will develop severe dengue, and also to the use of predictive marker(s) and to a kit to predict the development of severe dengue.
    Type: Grant
    Filed: January 23, 2013
    Date of Patent: January 9, 2018
    Assignee: BIOMERIEUX
    Inventor: Frédéric Bedin
  • Patent number: 9839671
    Abstract: Provided is a method for treatment and/or prophylaxis of a condition associated with T cell mediated chronic inflammatory disease by administration, to a patient, of a peptide comprising N?-SVTEQGAELSNEER-C? (SEQ ID NO: 1) or an analog thereof that inhibits T cell migration. Also provided is the peptide or its analog for use in the methods of treatment and/or prophylaxis of said condition. Also provided is a method for the treatment of Sjogren's syndrome by administration of a peptide comprising N?-SVTEQGAELSNEER-C? to a patient in need thereof.
    Type: Grant
    Filed: November 17, 2016
    Date of Patent: December 12, 2017
    Assignee: The University of Birmingham
    Inventors: George Edward Rainger, Parth Narendran, Helen McGettrick, Myriam Chimen
  • Patent number: 9822181
    Abstract: The present invention is directed to sequence-optimized CD 123×CD3 bi-specific monovalent diabodies that are capable of simultaneous binding to CD 123 and CD3, and to the uses of such diabodies in the treatment of hematologic malignancies.
    Type: Grant
    Filed: August 20, 2014
    Date of Patent: November 21, 2017
    Assignee: MacroGenics, Inc.
    Inventors: Ezio Bonvini, Leslie S. Johnson, Ling Huang, Paul A. Moore, Gurunadh Reddy Chichili, Ralph Froman Alderson
  • Patent number: 9737589
    Abstract: The present disclosure includes methods and compositions for the treatment or prevention of diseases and disorders characterized by excessive or misregulated cellular proliferations, including methods for the treatment of tumors. The methods involve the use of pharmaceutical compositions comprising at least one agent selected from the group consisting of a LIF preparation, a BMP preparation, a BMPR signalling activator, and a LIFR signalling activator. The disclosure also includes LIF preparations, BMP preparations, BMPR signalling activator, and LIFR signalling activators, and methods for the identification of LIF preparations, BMP preparations, BMPR signalling activator, and LIFR signalling activators. The disclosure also includes pharmaceutical compositions comprising at least one agent selected from the group consisting of a LIF preparation, a BMP preparation, a BMPR signalling activator, and a LIFR signalling activator.
    Type: Grant
    Filed: November 16, 2015
    Date of Patent: August 22, 2017
    Assignee: Stemgen S.P.A.
    Inventors: Angelo Luigi Vescovi, Brent Allen Reynolds
  • Patent number: 9725768
    Abstract: The present invention concerns methods for selecting and producing idiotype vaccines, and in particular methods for selecting and producing an idiotype vaccine for treatment of a B-cell derived malignancy in a subject based on the clonal profile (clonotype) of the malignancy; a method for producing an updated idiotype vaccine matched to a B-cell derived malignancy exhibiting a shifting clonal profile; and the high-fidelity idiotype vaccines produced using the methods. The invention also includes idiotype vaccines produced using the described methods and methods of treating B-cell derived malignancies using the produced vaccines.
    Type: Grant
    Filed: August 30, 2013
    Date of Patent: August 8, 2017
    Assignee: BIOVEST INTERNATIONAL, INC.
    Inventors: Carlos F. Santos, Amy M. Mccord, Mark Hirschel
  • Patent number: 9617345
    Abstract: The present invention discloses antibodies which bind human and Macaca fascicularis CEACAM5 proteins, as well as isolated nucleic acids, vectors and host cells comprising a sequence encoding said antibodies. The invention also discloses immunoconjugates comprising said antibodies conjugated or linked to a growth-inhibitory agent, and to pharmaceutical compositions comprising antibodies, or immunoconjugates of the invention. The antibodies or immunoconjugates of the invention are used for the treatment of cancer or for diagnostic purposes.
    Type: Grant
    Filed: May 19, 2015
    Date of Patent: April 11, 2017
    Assignee: SANOFI
    Inventors: Pierre-Francois Berne, Francis Blanche, Hervé Bouchard, Béatrice Cameron, Tarik Dabdoubi, Stéphanie Decary, Paul Ferrari, Alexey Rak
  • Patent number: 9597368
    Abstract: Provided is a method for treatment and/or prophylaxis of a condition associated with T cell mediated chronic inflammatory disease by administration, to a patient, of a peptide comprising N?-SVTEQGAELSNEER-C? (SEQ ID NO: 1) or an analog of the peptide that inhibits T cell migration. Also provided is the peptide or its analog for use in the methods of treatment and/or prophylaxis of the condition.
    Type: Grant
    Filed: January 14, 2013
    Date of Patent: March 21, 2017
    Assignee: The University of Birmingham
    Inventors: George Edward Rainger, Parth Narendran, Helen McGettrick, Myriam Chimen
  • Patent number: 9555034
    Abstract: The invention provides compositions and methods for treating skin cancer associated diseases. Specifically, the invention relates to topically administering a signaling pathway inhibitor or a related compound to treat pre-cancerous skin lesions, skin tumors, and their associated diseases or disorders.
    Type: Grant
    Filed: July 20, 2015
    Date of Patent: January 31, 2017
    Assignee: THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA
    Inventor: John T. Seykora
  • Patent number: 9475880
    Abstract: The invention provides antibodies that specifically bind to human CD134. Invention anti-human CD134 antibodies specifically bind to the extracellular domain of human CD134, including non-OX40 ligand (OX40L) binding domains on human CD134, which is expressed on e.g. activated human conventional effector CD4 and/or CD8 T lymphocytes (Teffs) and on activated human suppressive regulatory CD4 T lymphocytes (Tregs). Invention anti-human CD134 antibodies are useful (e.g. to empower Teffs anti-cancer effector function and/or to inhibit Tregs suppressive function) for cancer treatment.
    Type: Grant
    Filed: September 13, 2012
    Date of Patent: October 25, 2016
    Assignees: Biocerox Products, B.V., Janssen Pharmaceuticals, Inc.
    Inventors: Petrus Johannes Simons, Louis Boon
  • Patent number: 9321845
    Abstract: We provide an antibody capable of binding to an intracellular PRL-I or PRL-3 polypeptide, in which the antibody is capable of binding to an epitope bound by antibody 269, antibody 223 or antibody 318. Such anti-PRL antibodies may be capable of binding to intracellular PRL-I or PRL-3. They may be suitable for use as therapies against cancer or metastasis thereof, or in clinical diagnosis to identify PRL-3 or PRL-I positive patients.
    Type: Grant
    Filed: March 18, 2014
    Date of Patent: April 26, 2016
    Assignee: AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH
    Inventor: Qi Zeng
  • Patent number: 9283195
    Abstract: The invention encompasses methods and kits used in the identification of invasive glioblastoma based upon the expression of TROY. The methods and kits also allow prediction of disease outcome as well as therapeutic outcome.
    Type: Grant
    Filed: January 13, 2015
    Date of Patent: March 15, 2016
    Assignee: The Translational Genomics Research Institute
    Inventor: Nhan Tran
  • Patent number: 9273143
    Abstract: The present invention provides pharmaceutical compositions comprising an anti-ErbB3 antibody and an anti-EGFR antibody, and methods of use thereof. The compositions and methods of the present invention are useful for the treatment of various cancers and other diseases and disorders.
    Type: Grant
    Filed: November 18, 2013
    Date of Patent: March 1, 2016
    Assignee: Regeneron Pharmaceuticals, Inc.
    Inventors: Christopher Daly, Douglas MacDonald, Xunbao Duan
  • Patent number: 9226955
    Abstract: A composition, comprising: an enriched population of autophagosomes derived from a non-small cell lung carcinoma cell line, and wherein the enriched population of autophagosomes includes: one or more toll-like receptor agonists; one or more tumor antigens; and one or more damage-associated molecular pattern molecules. In this way, an off-the-shelf vaccine may be available to be administered in order to stimulate a targeted immune response in patients bearing different tumor types.
    Type: Grant
    Filed: October 23, 2013
    Date of Patent: January 5, 2016
    Assignees: UbiVac, LLC, Providence Health & Services-Oregon
    Inventors: Traci Hilton, Sandra Aung, Rieneke van de Ven, Christopher Paustian, Tarsem Moudgil, Christopher Dubay, Christopher Twitty, Hong-Ming Hu, Bernard A. Fox
  • Patent number: 9220775
    Abstract: The present invention relates to antibodies and antigen binding fragments thereof that bind the extracellular domain of the HER3 receptor and inhibit various HER3 receptor related functions via ligand-dependent and/or ligand-independent mechanisms. Also provided are compositions with increased half-life. In addition, the invention provides compositions and methods for diagnosing and treating diseases associated with HER3 mediated signal transduction.
    Type: Grant
    Filed: November 20, 2012
    Date of Patent: December 29, 2015
    Assignee: MedImmune LLC
    Inventors: Partha S. Chowdhury, David Tice, Zhan Xiao, Philipp Steiner, Krista Kinneer, Marlon Rebelatto
  • Patent number: 9220723
    Abstract: The present invention provides agents useful in the treatment of cancer, as well as systems for identifying and/or characterizing such agents, and systems for identifying and/or characterizing patient populations responsive to particular agents.
    Type: Grant
    Filed: June 23, 2011
    Date of Patent: December 29, 2015
    Assignee: BRANDEIS UNIVERSITY
    Inventors: Ruibao Ren, Benjamin Cuiffo